{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-265858","form_type":"8-K","ticker":"MAZE","cik":"0001842295","company_name":"Maze Therapeutics, Inc.","filed_at":"2026-06-10T20:15:18+00:00","discovered_at":"2026-06-10T20:17:00.345159+00:00","generated_at":"2026-06-10T20:22:59.420873+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Maze Therapeutics shareholders re-elect two directors, ratify auditor at 2026 annual meeting","bullets":["Quorum of 44,660,029 shares (89.75% of outstanding) present at June 8 meeting.","Jason Coloma re-elected with 35,792,536 votes for, 5,926,467 withheld.","Neil Kumar re-elected with 34,056,425 votes for, 7,662,578 withheld.","Ratification of Ernst & Young as auditor passed: 44,557,778 for, 728 against.","No broker non-votes on auditor ratification; 2,941,026 broker non-votes on director election."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-265858","json":"https://secwatch.observer/filing/0001193125-26-265858.json","markdown":"https://secwatch.observer/filing/0001193125-26-265858.md","text":"https://secwatch.observer/filing/0001193125-26-265858.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842295/000119312526265858/0001193125-26-265858-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842295/000119312526265858/d110541d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T20:22:59.420873+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"61957daaa979323e4dd65440228f938c93432c5d","claim":"Maze Therapeutics, Inc. shareholders approved To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-08 meeting.","evidence_excerpt":"Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm. Votes For Votes Against Abstentions Broker Non-Votes 44,557,778 728 101,523 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1842295/000119312526265858/0001193125-26-265858-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-08"}],"fact_type":"shareholder_vote"},{"claim_id":"baa6296327fa9cab80793cc74b30ec30133dcce5","claim":"Maze Therapeutics, Inc. shareholders approved To elect each of Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as a Class I director to serve until the Company's 2029 annual meeting of stockholders at the 2026-06-08 meeting.","evidence_excerpt":"Proposal 1: Election of Directors. Nominee Votes For Votes Withheld Broker Non-Votes Jason Coloma, Ph.D. 35,792,536 5,926,467 2,941,026 Neil Kumar, Ph.D. 34,056,425 7,662,578 2,941,026","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1842295/000119312526265858/0001193125-26-265858-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-08"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}